Juvaris BioTherapeutics

Juvaris BioTherapeutics develops adjuvanted vaccines and immunotherapeutics to treat cancer and infectious diseases.

Juvaris BioTherapeutics, Inc. is developing adjuvanted vaccines and immunotherapeutics to treat infectious disease and cancer. The Company's platform technology induces profound immunostimulation via cationic lipid-DNA (non-coding) complexes (CLDC). The Company's lead product candidate, JVRS-100, stimulates adaptive and innate immune responses at levels many fold higher than other drugs in its class. JVRS-100 is in clinical development as a vaccine adjuvant and an immunotherapeutic.